| Name | Title | Contact Details |
|---|---|---|
Andrew Fazzone |
Director, Information Security and | Profile |
Kurt Azarbarzin |
Chief Technology Officer | Profile |
Swiss-American Products dba as elta Skin and Wounc Care is a Carrollton, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Diabetes Technologies is a Thomasville, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Second Sight ® Medical Products, Inc., located in Sylmar, California, was founded in 1998 to create a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations, such as Retinitis Pigmentosa.
At VoxelCloud, our vision is to transform how medical practitioners work with and interpret medical images and clinical data using cloud computing and artificial intelligence, and to improve the lives of millions through accurate, accessible, and timely medical analytics.
Transgenomic is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is the global leader in cardiac genetic testing with a family of innovative products designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.